Cite
HARVARD Citation
van Hulst, M. et al. (2018). The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands. Journal of medical economics. pp. 38-46. [Online].